Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

Pasireotide has a broader somatostatin receptor binding profile than other somatostatin analogues. A 16-week, Phase II trial showed that pasireotide may be an effective treatment for acromegaly. An extension to this trial assessed the long-term efficacy and safety of pasireotide. This study was an o...

Descripción completa

Detalles Bibliográficos
Autores principales: Petersenn, Stephan, Farrall, Andrew J., Block, Christophe, Melmed, Shlomo, Schopohl, Jochen, Caron, Philippe, Cuneo, Ross, Kleinberg, David, Colao, Annamaria, Ruffin, Matthieu, Hermosillo Reséndiz, Karina, Hughes, Gareth, Hu, Ke, Barkan, Ariel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942632/
https://www.ncbi.nlm.nih.gov/pubmed/23529827
http://dx.doi.org/10.1007/s11102-013-0478-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942632/
https://www.ncbi.nlm.nih.gov/pubmed/23529827
http://dx.doi.org/10.1007/s11102-013-0478-0

Ejemplares similares